VRPX vs. ONCT, SHPH, ADXS, BPTH, PTEIQ, ASLN, CWBR, EVFM, PBLA, and PTPI
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Oncternal Therapeutics (ONCT), Shuttle Pharmaceuticals (SHPH), Ayala Pharmaceuticals (ADXS), Bio-Path (BPTH), PolarityTE (PTEIQ), ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Evofem Biosciences (EVFM), Panbela Therapeutics (PBLA), and Petros Pharmaceuticals (PTPI). These companies are all part of the "pharmaceutical products" industry.
Virpax Pharmaceuticals vs. Its Competitors
Virpax Pharmaceuticals (NASDAQ:VRPX) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.
Virpax Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.
Virpax Pharmaceuticals currently has a consensus target price of $75.00, indicating a potential upside of 19,636.84%. Oncternal Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,798.97%. Given Virpax Pharmaceuticals' higher probable upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than Oncternal Therapeutics.
Virpax Pharmaceuticals has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Oncternal Therapeutics' return on equity of -177.58% beat Virpax Pharmaceuticals' return on equity.
Virpax Pharmaceuticals has higher earnings, but lower revenue than Oncternal Therapeutics.
32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Oncternal Therapeutics had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for Oncternal Therapeutics and 0 mentions for Virpax Pharmaceuticals. Virpax Pharmaceuticals' average media sentiment score of 0.00 beat Oncternal Therapeutics' score of -0.26 indicating that Virpax Pharmaceuticals is being referred to more favorably in the media.
Summary
Oncternal Therapeutics beats Virpax Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRPX) was last updated on 7/2/2025 by MarketBeat.com Staff
